Effectiveness of Ustekinumab in Patients Suffering From Crohn's Disease With Extra-intestinal Manifestations or Immune‐Mediated Inflammatory Diseases in a Real-world Setting
Phase of Trial: Phase IV
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms TENOR
- Sponsors Janssen-Cilag
- 11 Jul 2019 Planned End Date changed from 30 Apr 2020 to 30 Apr 2021.
- 09 Oct 2018 Planned End Date changed from 31 Mar 2020 to 30 Apr 2020.
- 09 Oct 2018 Status changed from not yet recruiting to recruiting.